You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Factor VIII Deficiency Treatment Market Professional Research Report 2021-2027

Market Analysis and Insights: Global Factor VIII Deficiency Treatment Market
The research report studies the Factor VIII Deficiency Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Factor VIII Deficiency Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Factor VIII Deficiency Treatment Scope and Segment
The global Factor VIII Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Factor VIII Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
by Application, this report covers the following segments
Global Factor VIII Deficiency Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Rest of Europe
South Korea
Southeast Asia
Rest of Asia-Pacific
Latin America
Middle East & Africa
Saudi Arabia
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Factor VIII Deficiency Treatment key players in this market include:
Bayer HealthCare
Novo Nordisk
F. Hoffmann-La Roche
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
1 Market Overview of Factor VIII Deficiency Treatment
1.1 Factor VIII Deficiency Treatment Market Overview
1.1.1 Factor VIII Deficiency Treatment Product Scope
1.1.2 Factor VIII Deficiency Treatment Market Status and Outlook
1.2 Global Factor VIII Deficiency Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Factor VIII Deficiency Treatment Market Size by Region (2016-2027)
1.4 Global Factor VIII Deficiency Treatment Historic Market Size by Region (2016-2021)
1.5 Global Factor VIII Deficiency Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Factor VIII Deficiency Treatment Market Size (2016-2027)
1.6.1 North America Factor VIII Deficiency Treatment Market Size (2016-2027)
1.6.2 Europe Factor VIII Deficiency Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Factor VIII Deficiency Treatment Market Size (2016-2027)
1.6.4 Latin America Factor VIII Deficiency Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Factor VIII Deficiency Treatment Market Size (2016-2027)

2 Factor VIII Deficiency Treatment Market Overview by Type
2.1 Global Factor VIII Deficiency Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Factor VIII Deficiency Treatment Historic Market Size by Type (2016-2021)
2.3 Global Factor VIII Deficiency Treatment Forecasted Market Size by Type (2022-2027)
2.4 Hemophilia A Drugs
2.5 Hemophilia A Inhibitors Treatment
2.6 Von Willebrand Disease Treatment

3 Factor VIII Deficiency Treatment Market Overview by Application
3.1 Global Factor VIII Deficiency Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Factor VIII Deficiency Treatment Historic Market Size by Application (2016-2021)
3.3 Global Factor VIII Deficiency Treatment Forecasted Market Size by Application (2022-2027)
3.4 Hospitals
3.5 Clinics
3.6 Other

4 Factor VIII Deficiency Treatment Competition Analysis by Players
4.1 Global Factor VIII Deficiency Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Factor VIII Deficiency Treatment as of 2020)
4.3 Date of Key Players Enter into Factor VIII Deficiency Treatment Market
4.4 Global Top Players Factor VIII Deficiency Treatment Headquarters and Area Served
4.5 Key Players Factor VIII Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Factor VIII Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Factor VIII Deficiency Treatment Products, Services and Solutions
5.1.4 Pfizer Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Recent Developments
5.2 Takeda
5.2.1 Takeda Profile
5.2.2 Takeda Main Business
5.2.3 Takeda Factor VIII Deficiency Treatment Products, Services and Solutions
5.2.4 Takeda Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Takeda Recent Developments
5.3 Bayer HealthCare
5.3.1 Bayer HealthCare Profile
5.3.2 Bayer HealthCare Main Business
5.3.3 Bayer HealthCare Factor VIII Deficiency Treatment Products, Services and Solutions
5.3.4 Bayer HealthCare Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 CSL Recent Developments
5.4 CSL
5.4.1 CSL Profile
5.4.2 CSL Main Business
5.4.3 CSL Factor VIII Deficiency Treatment Products, Services and Solutions
5.4.4 CSL Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 CSL Recent Developments
5.5 Grifols
5.5.1 Grifols Profile
5.5.2 Grifols Main Business
5.5.3 Grifols Factor VIII Deficiency Treatment Products, Services and Solutions
5.5.4 Grifols Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Grifols Recent Developments
5.6 Novo Nordisk
5.6.1 Novo Nordisk Profile
5.6.2 Novo Nordisk Main Business
5.6.3 Novo Nordisk Factor VIII Deficiency Treatment Products, Services and Solutions
5.6.4 Novo Nordisk Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Novo Nordisk Recent Developments
5.7 F. Hoffmann-La Roche
5.7.1 F. Hoffmann-La Roche Profile
5.7.2 F. Hoffmann-La Roche Main Business
5.7.3 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Products, Services and Solutions
5.7.4 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 F. Hoffmann-La Roche Recent Developments
5.8 Kedrion
5.8.1 Kedrion Profile
5.8.2 Kedrion Main Business
5.8.3 Kedrion Factor VIII Deficiency Treatment Products, Services and Solutions
5.8.4 Kedrion Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 Kedrion Recent Developments
5.9 Octapharma
5.9.1 Octapharma Profile
5.9.2 Octapharma Main Business
5.9.3 Octapharma Factor VIII Deficiency Treatment Products, Services and Solutions
5.9.4 Octapharma Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 Octapharma Recent Developments
5.10 Biogen Idec
5.10.1 Biogen Idec Profile
5.10.2 Biogen Idec Main Business
5.10.3 Biogen Idec Factor VIII Deficiency Treatment Products, Services and Solutions
5.10.4 Biogen Idec Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Biogen Idec Recent Developments
5.11 BioMarin Pharmaceutical
5.11.1 BioMarin Pharmaceutical Profile
5.11.2 BioMarin Pharmaceutical Main Business
5.11.3 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Products, Services and Solutions
5.11.4 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 BioMarin Pharmaceutical Recent Developments
5.12 Sangamo Therapeutics
5.12.1 Sangamo Therapeutics Profile
5.12.2 Sangamo Therapeutics Main Business
5.12.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.12.4 Sangamo Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Sangamo Therapeutics Recent Developments
5.13 Spark Therapeutics
5.13.1 Spark Therapeutics Profile
5.13.2 Spark Therapeutics Main Business
5.13.3 Spark Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.13.4 Spark Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 Spark Therapeutics Recent Developments
5.14 Swedish Orphan Biovitrum
5.14.1 Swedish Orphan Biovitrum Profile
5.14.2 Swedish Orphan Biovitrum Main Business
5.14.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Products, Services and Solutions
5.14.4 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Swedish Orphan Biovitrum Recent Developments
5.15 Uniqure NV
5.15.1 Uniqure NV Profile
5.15.2 Uniqure NV Main Business
5.15.3 Uniqure NV Factor VIII Deficiency Treatment Products, Services and Solutions
5.15.4 Uniqure NV Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Uniqure NV Recent Developments
5.16 Amarna Therapeutics
5.16.1 Amarna Therapeutics Profile
5.16.2 Amarna Therapeutics Main Business
5.16.3 Amarna Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.16.4 Amarna Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 Amarna Therapeutics Recent Developments
5.17 Dimension Therapeutics
5.17.1 Dimension Therapeutics Profile
5.17.2 Dimension Therapeutics Main Business
5.17.3 Dimension Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.17.4 Dimension Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 Dimension Therapeutics Recent Developments

6 North America
6.1 North America Factor VIII Deficiency Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada

7 Europe
7.1 Europe Factor VIII Deficiency Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe

8 Asia-Pacific
8.1 Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific

9 Latin America
9.1 Latin America Factor VIII Deficiency Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America

10 Middle East & Africa
10.1 Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa

11 Factor VIII Deficiency Treatment Market Dynamics
11.1 Factor VIII Deficiency Treatment Industry Trends
11.2 Factor VIII Deficiency Treatment Market Drivers
11.3 Factor VIII Deficiency Treatment Market Challenges
11.4 Factor VIII Deficiency Treatment Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • PUBLISHED DATE: May, 2021
  • NO OF PAGES: 125